The Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double the manufacturing capacity of therapeutic nucleic acids in response to the rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (API). 

What are Therapeutic nucleic acids?

Therapeutic nucleic acids are short DNA and RNA molecules, also called therapeutic oligonucleotides or oligos. Which serve as the API for drugs targeting a growing number of diseases, including cancer, cardiovascular disease, and rare and infectious diseases.

Why do they matter?

“This investment reflects not only the strong demand for therapeutic oligos but also for the unmatched quality and service of our therapeutic oligo contract development and manufacturing organization (CDMO).” said Mike McMullen, Agilent president, and CEO. “It’s yet another example of our focus on investing in high-growth markets while also delivering on Agilent’s mission of improving the quality of life.”

The therapeutic oligos market is estimated at $1 billion and is projected to grow significantly annually over the next five years, reaching $2.4 billion in 2027. Adding two new manufacturing lines (known as Trains C and D) will enable Agilent to meet the growing demand for siRNA, antisense, and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.

he new Train C and D manufacturing lines will be based in Agilent’s Frederick, Colorado facility, where a Train B manufacturing line, announced in 2020, will go live later this year.

Read more about Agilent’s oligo API development and manufacturing services and background on oligos for therapeutics in Agilent’s media room.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets. Delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at To receive the latest Agilent news, subscribe to the Agilent Newsroom.